# A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

Study · id `cardio:ct-nct04074551` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04074551](<https://clinicaltrials.gov/study/NCT04074551>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04074551

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 145 participants.

## Technical summary

Registry record NCT04074551. Randomized; double masking; primary purpose treatment. Start 2019-07-16 (actual); primary completion 2020-03-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 145 participants (enrolled count; ClinicalTrials.gov record NCT04074551, source copy `cardio:ctgov-nct04074551-2020-11-30`, retrieved 2026-10-26)
- Started: 2019-07-16 (actual) (ClinicalTrials.gov record NCT04074551, source copy `cardio:ctgov-nct04074551-2020-11-30`, retrieved 2026-10-26)
- Primary completion: 2020-03-17 (actual) (ClinicalTrials.gov record NCT04074551, source copy `cardio:ctgov-nct04074551-2020-11-30`, retrieved 2026-10-26)
- Completion: 2020-03-17 (actual) (ClinicalTrials.gov record NCT04074551, source copy `cardio:ctgov-nct04074551-2020-11-30`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04074551, source copy `cardio:ctgov-nct04074551-2020-11-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04074551-2020-11-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
- Condition: Hypertension
- Condition: Dyslipidemias
- Intervention (Drug): HCP1701
- Intervention (Drug): Losartan
- Intervention (Drug): Amlodipine
- Intervention (Drug): Rosuvastatin and Ezetimibe
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia (`cardio:pubmed-37395974`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ed544159cd5be02224c14201b173939b655940bd4e53cab7e19f9253f2db847a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
